Healthsonix Inc. DL-,001

HealthSonix Files International PCT Patent Application for Its Sound Pressure Wave Technology


2006-11-01 08:00 ET - News Release

IRVINE, CA -- (MARKET WIRE) -- 11/01/06


HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) today announced that the company has filed a Patent Cooperation Treaty (PCT) application to reserve the right to later file foreign patent applications in other key markets around the world. With this filing, future applications will be accorded the same effective filing date as the US patent application.

"The enSonix and AquaSonix line of medical products rely on our unique sound pressure wave technology which represents a medical breakthrough in the fight against the pain of arthritis. Protecting that intellectual property remains a high priority and HealthSonix will use its resources to ensure that our products receive the strongest protection possible around the world," stated Dieter Doederlein, Vice President of Corporate Development.

The Patent Cooperation Treaty (PCT) was established to provide an efficient and cost-effective way to enter into the patenting process in many different countries at one time. Most of the countries in the world are signatories to the Paris Convention. The PCT permits the filing of an "international" patent application either immediately or within one year of the filing of a patent application in any of the member nations. This filing now gives HealthSonix the ability to file for additional international patents over the next 18 months while retaining the original US priority filing date.

HealthSonix Commences New Clinical Trials to Expand Medical Claims for AquaSonix Therapy
Thursday November 9, 11:30 am ET


IRVINE, CA--(MARKET WIRE)--Nov 9, 2006 -- HealthSonix, Inc. (Other OTC:HSXI.PK - News) (Frankfurt:H7S.F - News) today announced it has commenced a new AquaSonix Therapy clinical trial with patients suffering with pain from osteoarthritis of the knee. The study group has been randomly divided into two groups: one group receives the actual sound pressure wave treatments, while the second control or placebo group, does not.
ADVERTISEMENT


"This clinical study is a Prospective, Randomized, Double-Blind, Single-Centre, Eight Week Trial to Baseline," stated Dr. David Venturi, Medical Director of HealthSonix. "The study will examine pain, function and stiffness levels using the WOMAC questionnaire and life style changes using the SF36 instrument to monitor the patient\'s progress after 5 and 10 and 15 treatment sessions. A physician\'s examination and radiographs have been used to establish the osteoarthritis of the knee diagnosis."

"This study is part of our on-going research efforts to gather more condition-specific scientific evidence for our patent pending sound pressure wave technology, and thereby initiate application of additional medical claims, for disease specific chronic and acute pain conditions," added Dr. Venturi.

AquaSonix Therapy is a breakthrough medical treatment for people with pain, reduced mobility and diminishing flexibility. It\'s a therapeutic water program that combines sound pressure waves with individualized low impact exercises in warm water therapy pools.